Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding niacin formulations.

John A Pieper1

  • 1Division of Pharmacotherapy, University of North Carolina, Chapel Hill, USA.

The American Journal of Managed Care
|September 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity.

European journal of clinical pharmacology·2005
Same author

Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.

Pharmacotherapy·2005
Same author

Secondary prevention of coronary heart disease in the elderly.

The Annals of pharmacotherapy·2003
Same author

Primary prevention of coronary heart disease in the elderly.

The Annals of pharmacotherapy·2003
Same author

The role of clopidogrel in the management of acute coronary syndromes.

Clinical therapeutics·2003
Same author

Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2003

Niacin effectively treats dyslipidemias by improving lipid profiles and reducing cardiovascular events. Extended-release niacin offers improved efficacy with fewer side effects compared to other formulations.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Niacin is a key therapeutic agent for dyslipidemias, uniquely impacting all lipid profile components.
  • It significantly reduces LDL cholesterol, triglycerides, and lipoprotein (a), while increasing HDL cholesterol.
  • Niacin has demonstrated efficacy in reducing coronary events and overall mortality.

Purpose of the Study:

  • To compare the pharmacokinetic, efficacy, and safety profiles of different niacin formulations.
  • To highlight the advantages of extended-release (ER) niacin over immediate-release (IR) and sustained-release (SR) formulations.
  • To inform healthcare professionals about optimizing niacin therapy for patients.

Main Methods:

  • Review of existing literature on niacin formulations (IR, SR, ER).

Related Experiment Videos

  • Analysis of pharmacokinetic differences related to absorption and metabolism.
  • Comparison of efficacy and safety data across the three formulations.

    • Main Results:

    • Niacin ER provides efficacy comparable to IR niacin but with reduced flushing.
    • Niacin ER avoids the hepatotoxicity associated with SR niacin formulations.
    • Formulation differences significantly impact niacin's side effect profile and patient tolerability.

    Conclusions:

    • Niacin ER represents an improved therapeutic option for dyslipidemia management.
    • Understanding formulation-specific profiles is crucial for maximizing niacin's benefits and minimizing adverse effects.
    • Pharmacists play a vital role in patient education and optimizing niacin therapy.